BubbleFect is already making an impact. With 185 researchers across 99 organisations in 17 countries, our Alpha, Beta and early customer community spans some of the world's leading academic institutions, biotech companies and global pharma partners, and it is growing fast.

The diversity of cargo types in active use speaks to BubbleFect's versatility as a truly cargo-agnostic platform. From plasmid DNA and mRNA to CRISPR RNPs, proteins, peptides and saRNA. Researchers are putting BubbleFect to work across the full breadth of modern life sciences workflows. And the cell type data is equally compelling, from standard HEK293 and HeLa lines through to hiPSCs, primary fibroblasts, PBMCs, haematopoietic stem cells and beyond. BubbleFect is delivering where other reagents struggle.

With strong and growing inbound interest from across the scientific community, through referrals, conferences, digital campaigns and direct discovery — BubbleFect is rapidly establishing itself as the go-to non-viral, non-lipid delivery platform for researchers who demand more from their transfection reagent.